SB17170 Phase 2 Trial in IPF Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SB17170, Placebo.
- Who it may be relevant to
- Registry conditions: IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF). Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.
Overview
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
Detailed description
Idiopathic pulmonary fibrosis (IPF) is a progressive respiratory disease characterized by a scarring process of the lung, bringing patients to respiratory failure and death in 3-5 years from diagnosis.
Subjects who meet the inclusion/exclusion criteria as a result of the screening test shall be randomized into Test Group 1 (SB17170 A mg), Test Group 2 (SB17170 B mg) and Control Group (Placebo for SB17170) in 2:2:1. Subjects who have been randomized will orally take 2 capsules once daily after a meal according to their assigned administration group for 12 weeks from the date they are prescribed the investigational product.
Safety and tolerability at 12 weeks after randomization, and efficacy at 4 \& 12 weeks will be assessed. The subject who has completed 12 weeks of treatment shall visit the trial site after 1 week (Visit 7, EOS) for a follow-up.
Interventions
- Drug SB17170
Taking SB17170 orally once a day - Drug Placebo
Taking Placebo orally once a day
Primary outcome measures
- Change from baseline in FVC (ml) [Time frame: Week 12]
Secondary outcome measures (5)
- Change from baseline in FVC (%) [Time frame: Week 12]
- Change from baseline in DLCO [Time frame: Week 12]
- Change from baseline in quality of life and symptoms [Time frame: Week 12]
- Change from baseline in quality of life and symptoms [Time frame: Week 12]
- Change from baseline in quality of life and symptoms [Time frame: Week 12]
Eligibility criteria
Inclusion criteria
- Adult male/female 40 years or older at the time of obtaining informed consent
- Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:
- Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan
- Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit
- Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria
- Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit
- Patients meeting pulmonary function test criteria at the screening visit
- Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form
Exclusion criteria
- When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities
- Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period
- Patients with lower respiratory tract infections requiring antibiotic treatment
- Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial
- Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening
- Patients with evidence of active infection
- Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:
- Severe hypertension within 3 months
- Myocardial infarction or unstable angina within 6 months
- History of thrombotic events within 6 months
- Diagnosis of heart failure within 6 months
- Patients with pulmonary hypertension
- Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product
- Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
South Korea · 5 centers
- Myong Ji Hospital — Goyang
- Chung-Ang University Gwangmyeong Hospital — Gwangmyeong
- Seoul Asan Hospital — Seoul
- The Catholic Univ. of Korea Seoul St. Mary's Hospital — Seoul
- Ajou University Hospital — Suwon
Identifiers
NCT: NCT06747923 · SMARTT-004